Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective

BMC Proceedings

Dimo Gatev¹  Liana Gheorghe²  Olga Mitrović³  Zoya Spassova⁴  Eszter Schafer⁵  Željko Krznarić⁶  Srdjan Marković⁷  Klaudia Farkas⁸  Riina Salupere⁹  Laimas Jonaitis^1,10  Mateja Saje^1,11  Anton Lijović^1,12  Viktorija Mokricka^1,13  Isabella Grosu^1,14  Tina Roblek^1,15  Viktor Uršič^1,15  David Drobne^1,16 

[1] BABKUK Bulgarian patient organization ( Bulgarian Crohn and Ulcerative Colitis Association), Nikolai Kopernik 28-30, 1000, Sofia, Bulgaria;Center for Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute, Fundeni 258, 022328, Bucharest, Romania;Clinic for Gynecology and Obstetrics, University Clinical Centar of Serbia, Koste Todorovica 26, 11000, Belgrade, Serbia;Clinic of Gastroenterology, University Hospital “St. Ivan Rilski”, 1431, Sofia, Bulgaria;Department of Gastroenterology, Military Hospital Budapest, Podmaniczky u. 111, 1062, Budapest, Hungary;Department of Gastroenterology, University Hospital Center Zagreb, Kišpatićeva 12, 10 000, Zagreb, Croatia;Department of Gastroenterology, University Hospital Medical Center Zvezdara, Dimitrija tucovica 161, 11000, Belgrade, Serbia;Department of Gastroenterology, University of Szeged, Kálvária sgt. 57, 6725, Szeged, Hungary;Division of Gastroenterology, Tartu University Hospital, University of Tartu, Ludvig Puusepa 8, 50406, Tartu, Estonia;Gastroenterology clinic, Hospital of Lithuanian University of Health Sciences, Eiveniu str. 2, LT-50009, Kaunas, Lithuania;Inflammatory Bowel Disease Association (Društvo za kronično vnetno črevesno bolezen), Ljubljanska ulica 5, 2000, Maribor, Slovenia;Patient Organization HUCUK (Hrvatsko udruženje za Crohnovu bolest i ulcerozni colitis), Ulica Kralja Zvonimira 20, 10 000, Zagreb, Croatia;Pauls Stradiņš Clinical University Hospital, 13 Pilsoņu iela, 1002, Riga, LV, Latvia;Romanian IBD Patient Association, Traian 3, 910040, Calarasi, Romania;Takeda Pharmaceuticals d.o.o, Bleiweisova cesta 30, 1000, Ljubljana, Slovenia;University medical Centre Ljubljana, Zaloška cesta 2, 1000, Ljubljana, Slovenia;Medical Faculty, University of Ljubljana, Vrazov trg 2, 1000, Ljubljana, Slovenia;

关键词: Inflammatory bowel disease;    Subcutaneous administration;    Intravenous administration;    Biotherapeutics;    Compliance;    Quality of life;   

DOI  :  10.1186/s12919-021-00230-7

来源: Springer

【 摘 要 】

Several biologic treatments are available in addition to intravenous also in subcutaneous form for treatment of chronic diseases. Benefits of the subcutaneous application of drugs include self-administration by the patient, shorter time of application process with less infusion related adverse events and consequently lower healthcare costs. With appropriate education and support patients are able to administer their treatments at home. This leads to improvement of quality of life, reduction of time needed to travel to the healthcare institution and consequently also reduces costs also for the patient.Over one million residents in the USA and 2.5 million in Europe are estimated to have inflammatory bowel disease (IBD), with substantial costs for health care. These estimates do not factor in the ‘real’ price of IBD, which can impede career aspirations, instil social stigma and impair quality of life in patients.The Virtual Community Meeting, which offered an exchange of experience and opinions from healthcare professionals who are active in treating IBD, and patients with this chronic disease, revealed in-depth arguments and answers to some essential questions: which patients prefer subcutaneous over intravenous dosing; which patients continue to favour intravenous infusions; what are the limitations regarding both applications; what is the patient’s role in therapeutical decision-making and how does IBD affect the patient’s work, finances and quality of life? The aim of this article is to discuss the differences between subcutaneous and intravenous dosing from the health-economic, scientific, and personal perspectives.The meeting offered strong confirmation that most of the patients and healthcare professionals prefer subcutaneous over intravenous drug administration but emphasise the management of risks associated with treatment compliance. Patient education provided by the IBD team in this regard is mandatory. Quality of life of patients is poorer during active disease, but the findings that it can improve over time, including as a result of home- or self-administration of biologics, may be encouraging for individuals with this chronic disease.

【 授权许可】

CC BY